Volume : 10, Issue : 03, March – 2023
Title:
17.DEVELOPMENT AND VALIDATION OF A RP – HPLC METHOD FOR THE SIMULTANEOUS DETERMINATION OF NETUPITANT AND PALONOSETRON IN PURE AND PHARMACEUTICAL DOSAGE FORM
Authors :
Angadi Nagesh, Dr k. Balaji
Abstract :
New method was established for simultaneous estimation of Netupitant and Palonosetron by RP-HPLC method.The chromatographic conditions were successfully developed for the separation of Netupitant and Palonosetron by using Inertsil C18 (4.6mm ×250mm, 5µm particle size), flow rate was 1.0 ml/min, mobile phase ratio was (55:45% v/v) Methanol: Phosphate buffer pH 4.8 (pH was adjusted with ortho phosphoricacid), detection wavelength was 282nm. The instrument used was WATERS Alliance 2695 separation module, Software: Empower 2, 996 PDA detector. The retention times were found to be 1.688mins and 3.282mins. The % purity of Netupitant and Palonosetron was found to be 99.86%. The system suitability parameters for Netupitant and Palonosetron such as theoretical plates and tailing factor were found to be 7586, 1.69 and 6235 and 1.58, the resolution was found to be 10.85. The analytical method was validated according to ICH guidelines (ICH, Q2 (R1)). The linearity study of Netupitant and Palonosetron was found in concentration range of 100µg-500µg and 30µg-70µg and correlation coefficient (r2) was found to be 0.999 and 0.999, % recovery was found to be 100.112% and 100.16%, %RSD for repeatability was 0.1702 and 0.043 respectively. The precision study was precise, robust, and repeatable. The LOD value was found to be 2.1µg/ml and 1.28µg/ml, and LOQ value was 6.3µg/ml and 3.84µg/ml for Netupitant and Palonosetron respectively. The results of study showed that the proposed RP‐HPLC method is a simple, accurate, precise, rugged, robust, fast and reproducible, which may be useful for the routine estimation of Netupitant and Palonosetron in pharmaceutical dosage form.
Keywords: Netupitant, Palonosetron, RP‐HPLC, Simultaneous estimation.
Cite This Article:
Please cite this article in press Angadi Nagesh et al, Development And Validation Of A RP – HPLC Method For The Simultaneous Determination Of Netupitant And Palonosetron In Pure And Pharmaceutical Dosage Form.,Indo Am. J. P. Sci, 2023; 10(03).
Number of Downloads : 10
References:
1. De Leon A: Palonosetron (Aloxi): a second-generation 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting. Proc (Bayl Univ Med Cent). 2006 Oct;19(4):413-6.
2. Stoltz R, Cyong JC, Shah A, Parisi S: Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol. 2004 May;44(5):520-31.
3. Rubenstein EB: Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2004 May;2(5):284-9.
4. Darmani NA, Zhong W, Chebolu S, Mercadante F: Differential and additive suppressive effects of 5-HT3 (palonosetron)- and NK1 (netupitant)-receptor antagonists on cisplatin-induced vomiting and ERK1/2, PKA and PKC activation. Pharmacol Biochem Behav. 2015 Apr;131:104-11. doi: 10.1016/j.pbb.2015.02.010. Epub 2015 Feb 14. [Article]
5. Calcagnile S, Lanzarotti C, Rossi G, Henriksson A, Kammerer KP, Timmer W: Effect of netupitant, a highly selective NK(1) receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. Support Care Cancer. 2013 Oct;21(10):2879-87. doi: 10.1007/s00520-013-1857-9. Epub 2013 Jun 11
6. Lanzarotti C, Rossi G: Effect of netupitant, a highly selective NK(1) receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone. Support Care Cancer. 2013 Oct;21(10):2783-91. doi: 10.1007/s00520-013-1855-y. Epub 2013 Jun 1.
7. Narayudu Yandamuri, Development and Validation of RP-HPLC Method for Simultaneous Estimation of Netupitant and Palonosetron in Pharmaceutical Dosage Form, Research gate, February 2019.
8. P.Sri haritha, Dr. S. Shobha Rani, Dr. M. Ajitha, K. Rambabu, Stability indicating method development and validation for the simultaneous estimation of palonosetron and netupitant by RP-HPLC in its bulk form, journal of pharma research, November 2017.
9. NVMS Bhagavnji, PVV Satyanarayana,Karanam Sekhar, D. Naniprasad Development and Combined Tablet Dosage Form, International Journal of Pharmaceutical Sciences Review and Research, 41(1), November -December 2016; Article No. 17, Pages: 81-87.
10. Dr. Gampa Vijay Kumar1*, B. Sravanthi2, N. Gayathri Aparna3, Development and Validation of RP HPLC Method for Simultaneous Estimation of Netupitant and Palonosetron in Pharmaceutical Dosage Form. pharma research library2019.
11. Uttam Prasad Panigrahy1*, A. Sunil Kumar Reddy2, A novel validated RP-HPLC-DAD method for the simultaneous estimation of Netupitant and Palonosetron in bulk and pharmaceutical dosage form with forced degradation studies. International Journal of Chem Tech Research, Vol.8, No.10 pp 317-337.